Literature DB >> 22466233

[Neuromyelitis optica spectrum disorder: a case report].

Tetsuryu Mitsuyama1, Taku Yoneyama, Sakiko Suzuki, Mizuo Kagawa, Takakazu Kawamata.   

Abstract

Neuromyelitis optica (NMO) is a relapsing inflammatory disease of the central nervous system, usually affecting the optic nerves and the spinal cord. It is presumed to be an antibody-mediated disorder and the target antigen is the water channel aquaporin-4 (AQP4) on astrocyte cell membranes. NMO is a disease caused by astrocyte disorder and is distinct from multiple sclerosis (MS), which is a primarily demyelinating disease caused by oligodendrocyte disorder. In NMO, spinal MRI shows a T2-hyperintense, longitudinally extensive (≥ 3 vertebral segments) spinal cord lesion. The case, which has optic neuritis or transverse myelitis with the presence of AQP4 antibody, is called as NMO spectrum disorder. A 68 year-old woman with a history of hypertension and diabetes mellitus was brought to the former hospital by ambulance with acute onset of tetraparesis. She denied visual acuity disturbance. MRI revealed a T2-hyperintense lesion from C5 to T2 level. Laboratory examination showed the presence of AQP4 antibody and the absence of oligoclonal bands. Low-dose steroid treatment was started after establishing a diagnosis of NMO. She incompletely recovered from disability, although the T2-hyperintense lesion on MRI had almost disappeared six months after the onset. It is important to maintain a high index of suspicion for NMO in cases with a longitudinally extensive spinal cord lesion, because untreated NMO leads to severe disability.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22466233

Source DB:  PubMed          Journal:  No Shinkei Geka        ISSN: 0301-2603


  1 in total

1.  Neuromyelitis optica: atypical clinical and neuroradiological presentation.

Authors:  Alessandra Splendiani; Silvia Mariani; Monica Anselmi; Alessia Catalucci; Ernesto Di Cesare; Massimo Gallucci
Journal:  Neuroradiol J       Date:  2015-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.